新生儿卡介苗接种预防生命最初5年呼吸道感染:MIS BAIR随机对照试验结果
在澳大利亚低结核流行区开展的3期随机对照试验将1272名新生儿按1:1随机分为卡介苗组(接种BCG-Denmark)或无干预对照组,主要结局为生命最初5年因下呼吸道感染住院。多重插补分析显示,卡介苗组5年内下呼吸道感染住院调整发生率为9.6%,对照组为12.4%(调整风险差-2.8个百分点,95%CI -7.8至2.3),无明确证据表明卡介苗显著降低下呼吸道感染、感染或呼吸道疾病住院。
要点
- 1272名新生儿随机分组,卡介苗组5年内下呼吸道感染住院调整发生率9.6%,对照组12.4%。
- 调整风险差-2.8个百分点(95%CI -7.8至2.3),未见明确显著降低。
- 5年内14.2%的婴儿至少有一次因感染住院,第一年因感染住院的首因以下呼吸道感染为主(占首次住院的37%)。
核心结论
- 在低死亡率环境中,无明确证据表明新生儿卡介苗接种可显著降低生命早期因下呼吸道感染、感染或呼吸道疾病住院的发生率。
- 卡介苗效应的检出能力可能受随访期间缺失数据增加的限制。
研究设计与样本
- 在澳大利亚开展的3期随机对照试验(NCT01906853),新生儿按1:1随机接受BCG-Denmark接种(卡介苗组)或无干预(对照组)。
- 共1272名婴儿随机分组,采用家长报告问卷确定感染住院,主要结局按意向性治疗并用多重插补分析。
- 至5岁的完整病例数据 available 于1272名参与者中的711名(56%)。
主要发现
- 至5岁时,1272名随机婴儿中14.2%至少有一次因感染住院。
- 因感染住院的主要原因在生命第一年为下呼吸道感染(占首次住院的37%),至5岁时为上呼吸道感染(33%)。
- 多重插补分析中,卡介苗组5年内下呼吸道感染住院调整发生率为9.6%,对照组为12.4%(调整风险差-2.8个百分点;95%CI -7.8至2.3)。
- 次要结局中,卡介苗组的任何感染住院和任何呼吸道疾病住院也较低。
- 未观察到卡介苗对下呼吸道感染住院的效应与母亲卡介苗接种、性别或分娩方式之间存在交互作用。
局限性
- 卡介苗效应的检出能力可能受随访期间缺失数据增加的限制。
- 至5岁的完整病例数据仅 available 于1272名参与者中的711名(56%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Respiratory tract infections (RTI) are among the leading causes of hospitalisation and death for children under 5 years. We aimed to determine if neonatal BCG vaccination reduces early life hospitalisations for lower RTI (LRTI) in a low-tuberculosis endemic setting. METHODS: Neonates were randomised 1:1 to receive BCG-Denmark vaccination (BCG group) or no intervention (Control) in a phase 3 randomised controlled trial in Australia (NCT01906853). Hospitalisation for infection was determined by parent-reported questionnaires. The effect of BCG vaccination on the incidence of hospitalisation for LRTI in the first five years was analysed by intention-to-treat with multiple imputation. RESULTS: Complete case data to five years was available for 711 (56 %) of the 1272 participants. In the time-to-event analysis of the 1272 infants randomised, 14.2 % had one or more hospitalisations due to infection by five years. The predominant cause of hospitalisation for infection was LRTI in the first year of life (37 % of first hospitalisations), and upper RTI (33 %) by five years. In the multiple imputation analysis of the 1272 participants, the adjusted incidence of hospitalisation for LRTI in the first five years was 9.6 % in the BCG group compared to 12.4 % in the Control group (adjusted risk difference [aRD] -2.8 percentage points; 95 % CI -7.8 to 2.3). Secondary outcomes of hospitalisation for any infection and any respiratory illness were also lower in the BCG group. No interaction was observed between the effect of BCG vaccination on hospitalisation for LRTI and maternal BCG vaccination, sex or delivery mode. CONCLUSIONS: In a low-mortality setting, there was not clear evidence that neonatal BCG vaccination significantly reduces the incidence of early life hospitalisation for LRTI, infections or respiratory illness. The ability to detect any effect of BCG may have been limited by the increasing missing data over the course of follow-up.
引用
- Messina NL, Pittet LF, Forbes EK, et al. Neonatal BCG vaccination to prevent respiratory infections in the first 5 years of life: results from the MIS BAIR randomised controlled trial. Vaccine. 2025. PMID: 41337911. doi:10.1016/j.vaccine.2025.127958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。